Nisreen M A Okba

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3541730/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Severe Acute Respiratory Syndrome Coronavirus 2â^'Specific Antibody Responses in Coronavirus Disease Patients. Emerging Infectious Diseases, 2020, 26, 1478-1488.	4.3	1,389
2	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science, 2020, 369, 643-650.	12.6	1,104
3	A human monoclonal antibody blocking SARS-CoV-2 infection. Nature Communications, 2020, 11, 2251.	12.8	919
4	Phenotype and kinetics of SARS-CoV-2–specific T cells in COVID-19 patients with acute respiratory distress syndrome. Science Immunology, 2020, 5, .	11.9	851
5	Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science, 2020, 368, 1012-1015.	12.6	802
6	Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nature Communications, 2021, 12, 267.	12.8	601
7	SARS-CoV-2 is transmitted via contact and via the air between ferrets. Nature Communications, 2020, 11, 3496.	12.8	395
8	An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nature Communications, 2020, 11, 3436.	12.8	321
9	An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science, 2016, 351, 77-81.	12.6	216
10	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell, 2021, 184, 1188-1200.e19.	28.9	154
11	Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications, 2021, 12, 3189.	12.8	139
12	A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. Nature Communications, 2021, 12, 1715.	12.8	138
13	Susceptibility of rabbits to SARS-CoV-2. Emerging Microbes and Infections, 2021, 10, 1-7.	6.5	133
14	Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Lancet Infectious Diseases, The, 2020, 20, 827-838.	9.1	125
15	Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. Emerging Microbes and Infections, 2019, 8, 516-530.	6.5	99
16	Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections. Emerging Infectious Diseases, 2019, 25, 1868-1877.	4.3	80
17	Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection. Science Advances, 2018, 4, eaas9667.	10.3	66
18	Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	64

NISREEN M A OKBA

#	Article	IF	CITATIONS
19	Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches. Current Opinion in Virology, 2017, 23, 49-58.	5.4	60
20	Seasonal coronavirus–specific B cells with limited SARS-CoV-2 cross-reactivity dominate the lgG response in severe COVID-19. Journal of Clinical Investigation, 2021, 131, .	8.2	49
21	MERS-coronavirus: From discovery to intervention. One Health, 2017, 3, 11-16.	3.4	43
22	Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels. One Health, 2018, 5, 65-68.	3.4	39
23	Species-Specific Colocalization of Middle East Respiratory Syndrome Coronavirus Attachment and Entry Receptors. Journal of Virology, 2019, 93, .	3.4	33
24	A single subcutaneous or intranasal immunization with adenovirusâ€based SARSâ€CoVâ€2 vaccine induces robust humoral and cellular immune responses in mice. European Journal of Immunology, 2021, 51, 1774-1784.	2.9	30
25	Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein. Emerging Microbes and Infections, 2019, 8, 1593-1603.	6.5	29
26	SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model. Journal of Infectious Diseases, 2021, 223, 2020-2028.	4.0	28
27	Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV. Emerging Microbes and Infections, 2020, 9, 1080-1091.	6.5	26
28	Zika Virus Infection Induces Elevation of Tissue Factor Production and Apoptosis on Human Umbilical Vein Endothelial Cells. Frontiers in Microbiology, 2019, 10, 817.	3.5	22
29	MERS-CoV in Camels but Not Camel Handlers, Sudan, 2015 and 2017. Emerging Infectious Diseases, 2019, 25, 2333-2335.	4.3	21
30	Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus. Emerging Infectious Diseases, 2019, 25, 1878-1883.	4.3	16
31	Serologic Detection of Middle East Respiratory Syndrome Coronavirus Functional Antibodies. Emerging Infectious Diseases, 2020, 26, 1024-1027.	4.3	16
32	Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Seropositive Camel Handlers in Kenya. Viruses, 2020, 12, 396.	3.3	16
33	Experimental and field investigations of exposure, replication and transmission of SARS-CoV-2 in pigs in the Netherlands. Emerging Microbes and Infections, 2022, 11, 91-94.	6.5	11
34	Lack of Middle East Respiratory Syndrome Coronavirus Transmission in Rabbits. Viruses, 2019, 11, 381.	3.3	9
35	A poxvirus-based vaccine reduces virus excretion after MERS coronavirus infection in dromedary camels. International Journal of Infectious Diseases, 2016, 45, 421-422.	3.3	Ο
36	Two-Component Spike Nanoparticle Vaccine Protects Macaques from SARS-CoV-2 Infection. SSRN Electronic Journal, 0, , .	0.4	0